Pneumonia Therapeutics Market Size By Drug Class (Antibacterial Drugs, {Macrolide, Quinolones}, Antiviral Drugs, Antifungal Drugs), By Age Group (Paediatric, Adult, Geriatric), By Infection Type (Hospital-acquired Pneumonia [HAP], Community-acquired Pneumonia [CAP], Ventilator-associated Pneumonia [VAP]), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020 – 2026

Industry trends

Pneumonia Therapeutics Market size was USD 1.7 billion in 2019 and will grow at a CAGR of 7.6% from 2020 to 2026.
 

Get more details on this report - Request Free Sample PDF
 

Pneumonia is widely referred to as a disease condition that affects the alveoli of the lungs. Pneumonia is caused by fungi, bacteria or viruses and accounts for 5% of deaths among children below 5 years of age. Prevalence of pneumonia is significantly high in paediatric population of African countries. However, lack of accessibility to pneumonia therapeutics and treatment facilities has kept mortality rate higher in African countries.
 

Surging number of on-going clinical trials will propel the demand for pneumonia therapeutics

Increasing number of on-going clinical trials for the development of drug molecules will have a significant impact on the market progression. Currently, different companies operating in the pneumonia therapeutics market including Merck and GSK are putting enormous efforts in the research and development activities. For instance, in February 2020, FDA accepted the review supplemental new drug application for Recarbrio for the treatment of adults with ventilator-associated and hospital-acquired bacterial pneumonia. Introduction of such new drug molecules into will augment the market growth over the forecast timeframe. However, low treatment rates in developing economies as compared to developed may restrict the market growth over analysis timeframe.
 

Surging demand for antiviral drugs will favour the industry growth

Get more details on this report - Request Free Sample PDF
 

Antiviral drugs market segment will witness around 7.5% CAGR during the forecast period. Viral pneumonia spreads through fluid present in the air droplets after an individual coughs or sneezes. These fluids enter into the body through mouth or nose. Several treatment options including oseltamivir and acyclovir among others are used to treat the antiviral infection. Similarly, these drugs help to minimize the severity of flu virus spreading into the body that further augments the market progression.
 

According to American Thoracic Society 2019, viral pneumonia is the one of the leading cause of hospitalization among infants in the U.S. and rest of the world. Thus, rising prevalence of viral pneumonia drives the demand for pneumonia therapeutics drug.
 

Increasing need for pneumonia therapeutics among geriatric population will propel the market progression

Get more details on this report - Request Free Sample PDF
 

The geriatric segment accounted for around 20% market share in 2019 and is estimated to rise over the forecast period. Geriatric individuals are susceptible to pneumonia due to weak immune system. Diabetes, heart disease and other serious illness are very common in elderly individuals that eventually increases the risk of pneumonia. Furthermore, geriatric population base has greater chances of getting affected by flu as well as other lung-related disorders, that sometimes often develop into pneumonia.
 

Increasing number of hospital-acquired pneumonia infections will accelerate the overall pneumonia therapeutics market expansion

HAP market accounted for more than USD 352 Mn in 2019. Hospital-acquired pneumonia is a lung infection that occurs during hospital stays. Majority of patients with hospital-acquired pneumonia develop serious complications that include renal failure, respiratory failure and empyema due to severe and weak health conditions. Therefore, increasing incidences of hospital-acquired pneumonia will surge the demand for pneumonia therapeutics drugs.
 

Rising preference towards online pharmacies will offer significant market growth opportunities 

The online pharmacies market will exhibit around 8% CAGR during the forecast timeframe. Online pharmacies offer better pricing than offline stores with low product and transaction costs. Additionally, online pharmacies offer convenience and accessibility to people with limited mobility. Furthermore, these pharmacies provide doorstep delivery within a short period of time that increases their preference. Aforementioned factors will stimulate the pneumonia therapeutics industry growth during forecast timeframe.
 

Favorable government initiatives in Asia Pacific region will augment the market progression

Asia Pacific pneumonia therapeutics market held considerable revenue share in 2019 and accounted for more than 34% market share. Increasing prevalence of pneumococcal disease leading to weak immune systems will surge the demand for pneumonia therapeutics drugs. Furthermore, introduction of pneumonia related programs to control the prevalence of pneumonia in this region will favour the market growth. Thus, increasing number of favorable government initiatives will escalate the market demand over the forecast period.
 

Strategic initiatives undertaken by foremost market leaders have helped them evolve as major market players

Some of the prominent market players operating in the pneumonia therapeutics market share include Allergan, Bayer, Merck, Pfizer, Sanofi, Abbott, Cipla, GlaxoSmithKline, Lupin Pharmaceuticals, Novartis, and Mylan. These market players are undertaking various organic and inorganic growth strategies to capture higher market share in pneumonia therapeutics.
 

• In September 2018, Pfizer received breakthrough therapy designation from the U.S. FDA for its 20-Valent Pneumococcal Conjugate Vaccine. This vaccine is useful for the prevention of pneumonia and invasive disease. This strategy enhanced the company’s product portfolio.
   
• In June 2019, Merck received FDA approval for Zerbaxa drug. This drug is used in the treatment of ventilator associated pneumonia and hospital acquired bacterial pneumonia. This strategy widened the firm’s pneumonia therapeutics portfolio.
   

The pneumonia therapeutics industry research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2015 to 2026, for the following segments:

By Drug Class

• Antibacterial Drugs
  • Macrolide
  • Quinolones
  • Others
• Antiviral Drugs
• Antifungal Drugs

By Age Group

• Pediatric
• Adult
• Geriatric

By Infection Type

• Hospital-acquired pneumonia (HAP)
• Community-acquired pneumonia (CAP)
• Ventilator-associated pneumonia (VAP)

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Finland
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Philippines
  • Australia
• Latin America
  • Brazil
  • Mexico
  • Chile
  • Argentina
  • Peru
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel